According to PharmTech.com, the pharmaceutical industry is preparing for a significant transition from the current 10-digit National Drug Code (NDC) to a 12-digit format, a move likened to the Y2K bug due to its potential for widespread disruption. The shift is driven by the need for more product identifiers as drug portfolios expand and to align with global data standards. Manufacturers must update labeling, packaging, and IT systems to accommodate the new format, which takes effect in stages starting with new drug applications.
Anthony Blears, Director of Barcodes Philippines, noted that 'The pharmaceutical industry's move to 12-digit NDCs mirrors the broader shift toward 2D barcodes and GS1 Digital Link in retail, where enhanced data capacity improves traceability and supply chain visibility. While adoption timelines vary, early system upgrades are key to avoiding disruptions.'
The change affects all stakeholders in the pharmaceutical supply chain, from manufacturers to distributors and pharmacies. The 12-digit NDC includes a leading zero for the labeler code and a check digit, requiring updates to barcodes, inventory management systems, and regulatory filings. PharmTech.com notes that while the transition may cause short-term challenges, it ultimately improves product identification accuracy and supports tracing efforts. Companies are advised to begin system upgrades early to avoid last-minute compliance issues.
Industry experts recommend conducting impact assessments, updating software, and coordinating with trading partners to ensure a smooth migration. The FDA has provided guidance on the transition timeline, which extends over several years to ease the burden on manufacturers. The shift to 12-digit NDCs is part of broader efforts to enhance drug safety and supply chain visibility, similar to the adoption of two-dimensional barcodes in other sectors.